A combination of fludarabine, half-dose cyclophosphamide, and anti-thymocyte globulin is an effective conditioning regimen before allogeneic stem cell transplantation for aplastic anemia

被引:0
作者
Masahiro Ashizawa
Yu Akahoshi
Hirofumi Nakano
Tomotaka Ugai
Hidenori Wada
Ryoko Yamasaki
Yuko Ishihara
Koji Kawamura
Kana Sakamoto
Miki Sato
Kiriko Terasako
Shun-ichi Kimura
Misato Kikuchi
Hideki Nakasone
Shinichi Kako
Junya Kanda
Rie Yamazaki
Aki Tanihara
Junji Nishida
Yoshinobu Kanda
机构
[1] Jichi Medical University,Division of Hematology, Saitama Medical Center
来源
International Journal of Hematology | 2014年 / 99卷
关键词
HSCT; Fludarabine; Half-dose cyclophosphamide;
D O I
暂无
中图分类号
学科分类号
摘要
Conditioning regimens consisting of reduced-dose cyclophosphamide (CY) and fludarabine (FDR) have been investigated for use in allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with aplastic anemia to reduce the toxicities associated with CY. However, the ideal dose of CY has not been identified. In addition, little information is available regarding donor cell chimerism after allo-HSCT with these regimens. Therefore, we retrospectively analyzed 13 patients who underwent allo-HSCT with half-dose CY (100 mg/kg in total), FDR, and anti-thymocyte globulin at total doses of 2.5–10 mg/kg at our center. All the patients except one, who died due to encephalopathy on day 20, achieved neutrophil engraftment a median of 18.5 days after HSCT with complete donor-type chimerism. Two patients who received a graft from an HLA-matched donor subsequently developed mixed chimerism (MC) associated with transfusion-dependent cytopenia. One became transfusion-independent after donor lymphocyte infusion, but continues to exhibit MC. The other regained complete donor-type chimerism after the cessation of cyclosporine, but remains transfusion-dependent. These findings suggest that a conditioning regimen with half-dose CY and FDR is effective for achieving neutrophil engraftment and complete donor-type chimerism. However, subsequent MC may be observed, especially after HLA-matched HSCT.
引用
收藏
页码:311 / 317
页数:6
相关论文
共 166 条
[21]  
Arai S(2001)Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation Bone Marrow Transpl 28 689-476
[22]  
Horwitz M(2008)Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation Am J Hematol 83 472-572
[23]  
Antin JH(2002)Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: a prospective evaluation Transplantation 73 568-1060
[24]  
McCarty JM(1999)Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection Bone Marrow Transpl 23 1055-458
[25]  
Maury S(2013)Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics Bone Marrow Transpl 48 452-300
[26]  
Bacigalupo A(2013)In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation Am J Hematol 88 294-580
[27]  
Anderlini P(2013)Allogeneic stem cell transplantation using alemtuzumab-containing regimens in severe aplastic anemia Int J Hematol 97 573-722
[28]  
Aljurf M(2011)Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia Biol Blood Marrow Transpl 17 717-2216
[29]  
Marsh J(1999)Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study Blood 94 2208-undefined
[30]  
Socie G(undefined)undefined undefined undefined undefined-undefined